Varicella Vaccine
Chickenpox (Varicella) · Shingles (Zoster) — reduced lifetime risk
Varicella-zoster virus causes chickenpox — a highly contagious illness with itchy blisters, fever, and malaise. Before vaccination, nearly every American child contracted it. While often mild, severe complications including bacterial superinfection, pneumonia, encephalitis, and death occurred at meaningful rates. The same virus reactivates decades later as shingles.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The risk-benefit balance in your specific scenario suggests a detailed conversation with your child's provider before deciding.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Varicella-zoster virus causes chickenpox — a highly contagious illness with itchy blisters, fever, and malaise. Before vaccination, nearly every American child contracted it. While often mild, severe complications including bacterial superinfection, pneumonia, encephalitis, and death occurred at meaningful rates. The same virus reactivates decades later as shingles.
Chickenpox causes 5–7 days of significant discomfort, school absence, and parental work disruption. Invasive Group A strep superinfection (flesh-eating bacteria entering through scratched lesions) is a rare but life-threatening complication. Neonatal varicella (if mother infected near delivery) carries up to 30% fatality.
🛡️ Vaccine Effectiveness
Protection against severe disease is durable. Protection against mild infection wanes somewhat over 10+ years — breakthrough infections occur in ~15–20% of vaccinated individuals but are universally mild (fewer lesions, no fever, faster resolution).
Breakthrough chickenpox is real but mild. Important: vaccinated children who do get breakthrough are less likely to transmit to others.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Two doses recommended for all susceptible children, adolescents, and adults without evidence of immunity. Adults with no prior disease or vaccination should receive 2 doses 4–8 weeks apart.
⚖️ Benefits vs. Considerations
✓ Benefits
- 97% reduction in varicella hospitalizations since vaccine introduction in the US
- Near elimination of varicella deaths in children
- Prevents serious complications: invasive GAS superinfection, pneumonia, encephalitis
- Protects immunocompromised household members who cannot receive the vaccine
- Reduces lifetime shingles risk (vaccine-strain virus less likely to reactivate than wild-type)
- Eliminates socioeconomic burden: school closures, parental work absence, childcare costs
↕ Considerations
- 82% effectiveness against any infection — breakthrough cases occur in ~15–20% of vaccinated individuals
- Vaccine-strain rash (uncommon but possible) — looks like mild chickenpox; can rarely transmit to contacts
- UK chose not to add to routine schedule — legitimate scientific debate about population-level shingles risk
- 2-dose schedule requires second visit at 4–6 years
- Gelatin allergy contraindicates vaccine
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The UK JCVI twice declined universal vaccination based on modeling showing that reducing circulation of wild-type virus may reduce the natural immune boosting that prevents shingles in adults — potentially increasing population-level shingles morbidity even as chickenpox declines (Edmunds & Brisson, 2002; Pinot de Moira et al., 2018).
- Some health economists argue that the cost-effectiveness calculation depends heavily on whether productivity losses from parental caregiving are included — removing them narrows the benefit substantially in moderate-income countries.
- The 2-dose effectiveness is approximately 82% against any infection, meaning vaccinated children still contribute to transmission clusters in partially vaccinated schools — raising the question of whether herd immunity thresholds are achievable with current vaccine platforms.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Whether widespread childhood vaccination has paradoxically increased adult shingles rates by reducing natural immune boosting from exposure to wild-type virus (the 'exogenous boosting' hypothesis — supported by some models, contested by others)
- Long-term impact of shifting disease burden from children to adults in partially vaccinated populations
- Duration of vaccine-induced protection against shingles in vaccinated cohorts now entering adulthood
💉 Related Vaccines
Vaccines often given together or covering related diseases.
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.